Advanced Materials · 2021 · 69 citations · 23 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor MicroenvironmentAntitumor T Cell ResponsesCancer ImmunotherapyCancer NanomedicineImmunotherapy For Solid TumorsNanomedicineT Cell ExhaustionCancer NanotherapyImmunosuppressive MicroenvironmentProgrammed Cell Death Ligand 1 InhibitionProgrammed Death-ligand 1 InhibitionProgrammed Death-ligand 1 InhibitorsProgrammed Death-ligand 1 SignalingT Cell-based ImmunotherapyT-cell Therapy
Although T-cell therapy is a remarkable breakthrough in cancer immunotherapy, the therapeutic efficacy is limited for solid tumors. A major cause of the low efficacy is T-cell exhaustion by immunosuppressive mechanisms of solid tumors, which are mainly mediated by programmed death-ligand 1 (PD-L1) and transforming growth factor-beta (TGF-β). Herein, T-cell-derived nanovesicles (TCNVs) produced by the serial extrusion of cytotoxic T cells through membranes with micro-/nanosized pores that inhibit T-cell exhaustion and exhibit antitumoral activity maintained in the immunosuppressive tumor microenvironment (TME) are presented. TCNVs, which have programmed cell death protein 1 and TGF-β receptor on their surface, block PD-L1 on cancer cells and scavenge TGF-β in the immunosuppressive TME, thereby preventing cytotoxic-T-cell exhaustion. In addition, TCNVs directly kill cancer cells via granzyme B delivery. TCNVs successfully suppress tumor growth in syngeneic-solid-tumor-bearing mice. Taken together, TCNV offers an effective cancer immunotherapy strategy to overcome the tumor's immunosuppressive mechanisms.
23
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · New England Journal of Medicine · 2017 · 5.9K citations · Full text
Medicine, Hematology, Oncology +16
WanJun Chen, Wenwen Jin, Neil J. Hardegen et al. · The Journal of Experimental Medicine · 2003 · 4.6K citations · Full text